Like the number of biotech initial public offerings (IPOs) that are completed annually, another closely tracked statistic is the transactional value of the industry's mergers and acquisitions (M&As) and partnering deal flow. The number of deals concluded each year provides a measure of the vibrancy of the sector, its business strategies and technology aspirations.